Loading...
Market
What will be Cassava Sciences' financial status by end of 2024?
3
Resolution / Starting Odds
Profitable • 25%
Break-even • 25%
Loss-making but stable • 25%
Facing financial distress • 25%
Financial statements released by Cassava Sciences or financial news reports
Story
Cassava's Simufilam Fails ReThink-ALZ Phase 3 Trial; Shares Plunge 80%
Nov 25, 2024, 12:35 PM
Cassava Sciences announced on November 25th that its Phase 3 ReThink-ALZ trial of simufilam, a treatment for mild-to-moderate Alzheimer's disease, failed to meet co-primary endpoints. The drug did not show a significant reduction in cognitive or functional decline versus placebo. Consequently, the company plans to discontinue the second Phase 3 ReFocus-ALZ trial and the Open Label Extension study. Shares of Cassava Sciences fell over 80% following the announcement. The company stated that simufilam continued to demonstrate an overall favorable safety profile and has $149 million in cash reserves.
View original story
Similar markets
Revenue increases by 10% or more • 25%
Revenue stays within 10% of current levels • 25%
Revenue decreases by 10% or more • 25%
Cassava Sciences reports a loss • 25%
Above $200 million • 25%
Between $100 million and $200 million • 25%
Between $50 million and $100 million • 25%
Below $50 million • 25%
Less than $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
Over $1 billion • 25%
Below $20 • 25%
$20 to $40 • 25%
$40 to $60 • 25%
Above $60 • 25%
Below $1 billion • 25%
$1 billion to $1.5 billion • 25%
$1.5 billion to $2 billion • 25%
Above $2 billion • 25%
Stock price above $50 • 25%
Stock price between $20 and $50 • 25%
Stock price between $5 and $20 • 25%
Stock price below $5 • 25%
Outperforms • 33%
Performs similarly • 34%
Underperforms • 33%
Favorable ruling for Cassava Sciences • 25%
Unfavorable ruling for Cassava Sciences • 25%
Settlement • 25%
Case dismissed • 25%